Advertisement

Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service

      Abstract

      Purpose

      The aim of this study was to evaluate the cost-effectiveness and net monetary benefit of olaparib maintenance therapy compared with no maintenance therapy after first-line platinum-based chemotherapy in newly diagnosed advanced BRCA1/2-mutated ovarian cancer from the Italian National Health Service (NHS) perspective.

      Methods

      We developed a lifetime Markov model in which a cohort of patients with newly diagnosed advanced BRCA1/2-mutated ovarian cancer was assigned to receive either olaparib maintenance therapy or active surveillance (Italian standard of care) after first-line platinum-based chemotherapy to compare cost-effectiveness and net monetary benefit of the 2 strategies. Data on clinical outcomes were obtained from related clinical trial literature and extrapolated using parametric survival analyses. Data on costs were derived from Italian official sources and relevant real-world studies. The incremental cost-effectiveness ratio (ICER), incremental cost-utility ratio (ICUR), and incremental net monetary benefit (INMB) were computed and compared against an incremental cost per quality-adjusted life-year (QALY) gained of €16,372 willingness-to-pay (WTP) threshold. We used deterministic sensitivity analysis (DSA) and probabilistic sensitivity analysis (PSA) to assess how uncertainty affects results; we also performed scenario analyses to compare results under different pricing settings.

      Findings

      In the base-case scenario, during a 50-year time horizon, the total costs for patients treated with olaparib therapy and active surveillance were €124,359 and €97,043, respectively, and QALYs gained were 7.29 and 4.88, respectively, with an ICER of €9,515 per life-year gained, an ICUR of €11,345 per QALY gained, and an INMB of €12,104. In scenario analyses, considering maximum selling prices for all other drugs, ICUR decreased to €11,311 per QALY and €7,498 per QALY when a 10% and 20% discount, respectively, was applied to the olaparib official price, and the INMB increased to €12,186 and €21,366, respectively. DSA found that the model results were most sensitive to the proportion of patients with relapsing disease in response to platinum-based chemotherapy, time receiving olaparib first-line maintenance treatment, and subsequent treatments price. According to PSAresults, olaparib was associated with a probability of being cost-effective at a €16,372 per QALY WTP threshold ranging from 70% to 100% in the scenarios examined.

      Implications

      Our analysis indicates that olaparib maintenance therapy may deliver a significant health benefit with a contained upfront cost during a 50-year time horizon, from the Italian NHS perspective, providing value in a setting with curative intent.

      Key words

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • WHO International Agency for Research on Cancer
        Global cancer observatory (GCO).
        (Available from:)
      1. GLOBOCAN 2018 Cancer Incidence And Mortality Worldwide: IARC Cancer Base. International Agency for Research on Cancer, 2019
        • Doubeni C.A.
        • Doubeni A.R.B.
        • Myers A.E.
        Diagnosis and management of ovarian cancer.
        Am Fam Physician. 2016; 93: 937-944
        • Lisio M.A.
        • Fu L.
        • Goyeneche A.
        • Gao Z.H.
        • Telleria C.
        High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints.
        Int J Mol Sci. 2019; 20: 952
        • Jelovac D.
        • Armstrong D.K.
        Recent progress in the diagnosis and treatment of ovarian cancer.
        CA Canc J Clin. 2011; 61: 183-203
        • Bowtell D.D.
        • Bohm S.
        • Ahmed A.A.
        • et al.
        Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
        Nat Rev Canc. 2015; 15: 668-679
        • Huang Y.W.
        Association of BRCA1/2 mutations with ovarian cancer prognosis: an updated meta-analysis.
        Medicine (Baltimore). 2018; 97: e9380
        • Neff R.T.
        • Senter L.
        • Salani R.
        BRCA mutation in ovarian cancer: testing, implications and treatment considerations.
        Ther Adv Med Oncol. 2017; 9: 519-531
        • Weiderpass E.
        • Tyczynski J.E.
        Epidemiology of patients with ovarian cancer with and without a BRCA1/2 mutation.
        Mol Diagn Ther. 2015; 19: 351-364
        • Colombo N.
        • Sessa C.
        • du Bois A.
        • et al.
        ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease dagger.
        Ann Oncol. 2019; 30: 672-705
        • Ledermann J.A.
        • Raja F.A.
        • Fotopoulou C.
        • Gonzalez-Martin A.
        • Colombo N.
        • Sessa C.
        Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2013; 24: vi24-vi32
        • Burger R.A.
        • Brady M.F.
        • Bookman M.A.
        • et al.
        Incorporation of bevacizumab in the primary treatment of ovarian cancer.
        N Engl J Med. 2011; 365: 2473-2483
        • Tewari K.S.
        • Burger R.A.
        • Enserro D.
        • et al.
        Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer.
        J Clin Oncol. 2019; 37: 2317-2328
        • Coleman R.L.
        • Oza A.M.
        • Lorusso D.
        • et al.
        Rucaparib Maintenance Treatment for Recurrent Ovarian Carcinoma after Response to Platinum Therapy (ARIEL3): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial.
        390. Lancet, London, England)2017: 1949-1961
        • Mirza M.R.
        • Monk B.J.
        • Herrstedt J.
        • et al.
        Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer.
        N Engl J Med. 2016; 375: 2154-2164
        • Pujade-Lauraine E.
        • Ledermann J.A.
        • Selle F.
        • et al.
        Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
        Lancet Oncol. 2017; 18: 1274-1284
      2. ClinicalTrials.gov. Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy (SOLO-1) https://clinicaltrials.gov/ct2/show/NCT01844986. Last accessed: May 18, 2020.

        • Moore K.
        • Colombo N.
        • Scambia G.
        • et al.
        Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer.
        N Engl J Med. 2018; 379: 2495-2505
        • U.S. Food and Drug Administration (FDA)
        FDA Approved Olaparib (LYNPARZA, AstraZeneca Pharmaceuticals LP) for the Maintenance Treatment of Adult Patients with Deleterious or Suspected Deleterious Germline or Somatic BRCA-Mutated (gBRCAm or sBRCAm) Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Are in Complete or Partial Response to First-Line Platinum-Based.
        (Available from)19 December 2018
        • European Medicines Agency Committee for Medicinal Products for Human Use (EMA/CHMP)
        Summary of Opinion (Post Authorisation).
        (Available from)28 February 2019
        • Ledermann J.A.
        Front-line therapy of advanced ovarian cancer: new approaches.
        28. Ann Oncol, 2017: viii46-viii50
        • Woods B.
        • Revill P.
        • Sculpher M.
        • Claxton C.
        Country-level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research.
        CHE Research Paper, 2016: 109
        • TreeAge Software W. MA
        TreeAge Pro 2019, R2.
        (software available at:)
        http://www.treeage.com
        Date accessed: May 18, 2020
        • Italian Association of Medical Oncology (AIOM)
        Linee Guida - Tumori Dell'ovaio.
        2018
        • Ledermann J.A.
        • Sessa C.
        • Colombo N.
        Ovarian cancer.
        Ann Oncol. 2016; 27 (appendix 7) (eUpdate published online September 2016): v145
        • Aghajanian C.
        • Blank S.V.
        • Goff B.A.
        • et al.
        OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
        J Clin Oncol. 2012; 30: 2039-2045
        • National Institute for Health and Care Excellence (NICE)
        Olaparib for Maintenance Treatment of BRCA-Mutated Ovarian, Fallopian Tube and Peritoneal Cancer after Response to First-Line Platinum-Based Chemotherapy [ID1124].
        2019
        • Capri S.
        • Ceci A.
        • Terranova L.
        • Merlo F.
        • Mantovani L.
        Guidelines for economic evaluations in Italy: recommendations from the Italian group of pharmacoeconomic studies.
        Drug Info J. 2001; 35: 189-201
      3. Plot Digitizer.
        (Available from:)
        http://plotdigitizer.sourceforge.net/
        Date accessed: May 18, 2020
        • Wei Y.
        • Royston P.
        Reconstructing time-to-event data from published Kaplan-Meier curves.
        Stata J. 2017; 17: 786-802
        • Guyot P.
        • Ades A.E.
        • Ouwens M.J.
        • Welton N.J.
        Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.
        BMC Med Res Methodol. 2012; 12: 9
        • Diaby V.
        • Adunlin G.
        • Montero A.J.
        Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial.
        Pharmacoeconomics. 2014; 32: 101-108
        • Latimer N.
        NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data.
        (Available from:)
        • Cress R.D.
        • Chen Y.S.
        • Morris C.R.
        • Petersen M.
        • Leiserowitz G.S.
        Characteristics of long-term survivors of epithelial ovarian cancer.
        Obstet Gynecol. 2015; 126: 491-497
        • Javellana M.
        • Hoppenot C.
        • Lengyel E.
        The road to long-term survival: surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
        Gynecol Oncol. 2019; 152: 228-234
        • Italian National Institute of Statistics (ISTAT)
        Tavole di mortalità della popolazione residente.
        (Available from)2019
        • Colombo N.
        • Kutarska E.
        • Dimopoulos M.
        • et al.
        Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
        J Clin Oncol. 2012; 30: 3841-3847
        • Ferrandina G.
        • Ludovisi M.
        • Lorusso D.
        • et al.
        Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
        J Clin Oncol. 2008; 26: 890-896
        • Monk B.J.
        • Herzog T.J.
        • Kaye S.B.
        • et al.
        Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
        J Clin Oncol. 2010; 28: 3107-3114
        • Bartoletti M.
        • Pelizzari G.
        • Gerratana L.
        • et al.
        Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer (rOC)? A network meta-analysis (NMA).
        J Clin Oncol. 2019; 37: 5564
        • National Institute for Health and Care Excellence (NICE)
        Bevacizumab in Combination with Gemcitabine and Carboplatin for Treating the First Recurrence of Platinum-Sensitive Advanced Ovarian Cancer.
        2013
        • National Institute for Health and Care Excellence (NICE)
        Rucaparib for Maintenance Treatment of Relapsed Platinum-Sensitive Ovarian, Fallopian Tube or Peritoneal Cancer [ID1485].
        2019
        • Italian Medicines Agency (AIFA)
        Riclassificazione del medicinale per uso umano «Lynparza» ai sensi dell'articolo 8, comma 10, della legge 24 dicembre 1993.
        (Determina DG 888/2019). GU n. 140 del 17 giugno 2019)n. 537. 2019
        • Italian Medicines Agency (AIFA)
        Regime di rimborsabilita' e prezzo di vendita del medicinale «Yondelis (trabectedina)» - autorizzata con procedura centralizzata europea dalla Commissione europea.
        (Determinazione/C n 244/2009)2009 (GU n. 21 del 27 gennaio 2009)
        • Italian Medicines Agency (AIFA)
        Regime di rimborsabilita' e prezzo a seguito di nuove indicazioni terapeutiche del medicinale «Caelyx» (doxorubicina cloridrato liposomiale pegilata).
        (Determinazione/C n. 322/2009)2009 (GU n. 6 del 9 gennaio 2010)
        • Italian Medicines Agency (AIFA)
        Regime di rimborsabilita' e prezzo a seguito di nuove indicazioni terapeutiche del medicinale per uso umano «Avastin».
        (Determina n. 1220/2016)2016 (GU n. 231 del 3 ottobre 2016)
        • Italian Medicines Agency (AIFA)
        Regime di rimborsabilita' e prezzo del medicinale per uso umano «Zejula».
        (Determina n. 1362/2018)2018 (GU n. 219 del 20 settembre 2018)
        • Italian Medicines Agency (AIFA)
        Riclassificazione del medicinale per uso umano «Rubraca» ai sensi dell'art. 8, comma 10, della legge 24 dicembre 1993.
        (Determina n. DG/1508/2019)n. 537. 2019 (GU n. 265 del 12 novembre 2019)
      4. Italian Medicines Agency (AIFA), Elenchi farmaci di classe A e H.

        • Guy H.
        • Walder L.
        • Fisher M.
        Cost-effectiveness of niraparib versus routine surveillance, olaparib and rucaparib for the maintenance treatment of patients with ovarian cancer in the United States.
        Pharmacoeconomics. 2019; 37: 391-405
        • Italian Ministry of Health
        Decreto del Ministero della salute 18 ottobre 2012, allegato 1, "Tariffe delle prestazioni di assistenza ospedaliera per acuti, per tipo di ricovero.
        (Available from:)
        • Guest J.F.
        • Ruiz F.J.
        • Greener M.J.
        • Trotman I.F.
        Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK.
        Eur J Canc Care (Engl). 2006; 15: 65-73
        • Migliorino M.R.
        • Santo A.
        • Romano G.
        • et al.
        Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study.
        J Canc Res Clin Oncol. 2017; 143: 783-791
        • National Institute for Health and Care Excellence (NICE)
        Niraparib for Maintenance Treatment of Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer [ID1041].
        2018
        • National Institute for Health and Care Excellence (NICE)
        Olaparib for Maintenance Treatment of Relapsed, Platinum-Sensitive, BRCA Mutation-Positive Ovarian, Fallopian Tube and Peritoneal Cancer after Response to Second-Line or Subsequent Platinum-Based Chemotherapy [ID735].
        2016
        • Italian Ministry of Health
        Nomenclatore dell’assistenza specialistica ambulatoriale.
        (Available from:)